Business Context and Reporting Period
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for serious illnesses driven by inflammatory processes, primarily targeting calcium release-activated calcium (CRAC) channels. The company's lead product candidate is Auxora (zegocractin), currently in Phase 2 trials for acute kidney injury (AKI) and acute pancreatitis (AP). This Form 10-Q covers the quarterly period ended June 30, 2025. The company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(5.96) million | $(3.95) million | $(11.00) million | $(3.82) million |
| Operating Expenses | $6.62 million | $6.53 million | $13.12 million | $12.30 million |
| Cash & Equivalents | $5.92 million | $5.06 million | $5.92 million | $5.06 million |
| Short-term Investments | $12.04 million | $10.73 million | $12.04 million | $10.73 million |
| Total Liquidity | $17.96 million | $15.79 million | $17.96 million | $15.79 million |
| Long-term Debt (Promissory Note) | $8.50 million | $0 | $8.50 million | $0 |
| Warrant Liability | $1.00 million | $3.30 million | $1.00 million | $3.30 million |
| Accumulated Deficit | $(170.76) million | $(149.89) million | $(170.76) million | $(149.89) million |
Note: All figures in millions unless otherwise noted. The company has no product revenue.
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss for the six months ended June 30, 2025, increased to $11.0 million from $3.8 million in the prior year period. This increase was driven by higher operating expenses and interest expense, partially offset by a decrease in gains from the fair value adjustment of financial instruments.
- Debt Financing: In February 2025, the company entered into a Loan Agreement with Avenue Venture Opportunities Fund II, L.P., securing an initial $10.0 million tranche. This resulted in a new long-term promissory note liability of $8.5 million (fair value) and associated interest expense of $0.8 million for the six-month period.
- Operating Expenses: Research and development (R&D) expenses increased by 17% year-over-year for the six-month period to $8.3 million, primarily due to increased preclinical and clinical trial activities for Auxora. General and administrative (G&A) expenses decreased by 7% to $4.8 million, driven by lower transaction costs compared to the 2024 private placement.
- Other Income: Total other income decreased significantly to $2.1 million for the six months ended June 30, 2025, compared to $8.5 million in the prior year. This was primarily due to a reduction in the gain from fair value adjustments of warrant liabilities and promissory notes.
Guidance, Outlook, and Risks
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern. Based on current operating plans, the company believes its cash, cash equivalents, and short-term investments ($18.0 million) may not be sufficient to fund operations for one year following the issuance of the financial statements, projecting a runway into the middle of 2026.
- Clinical Outlook: The company is conducting a Phase 2 trial (KOURAGE) for Auxora in AKI with data expected in early 2026. Additional FDA meetings regarding the design of a pivotal trial for acute pancreatitis are anticipated in the second half of 2025.
- Capital Needs: The company will need to obtain substantial additional funding to complete the development and commercialization of its product candidates. Failure to raise capital could force the company to delay, reduce, or eliminate development programs.
- Key Risks:
- Dependence on the success of Auxora and the ability to obtain regulatory approval.
- Reliance on third-party manufacturers and CROs, including a single-source supplier in China for active pharmaceutical ingredients.
- Potential dilution from future equity financings or restrictive covenants from debt financing.
- Uncertainty regarding the acceptance of clinical trial data conducted outside the U.S. (e.g., in India).
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for the "middle of 2026" liquidity projection and the assumptions regarding burn rate.
- Debt Covenants: Review the specific milestones required to draw down Tranche 2 ($7.5M) and Tranche 3 ($15.0M) of the Avenue Loan Agreement and the restrictions on incurring additional indebtedness.
- Clinical Milestones: Confirm the enrollment status and data readout dates for the KOURAGE (AKI) trial and the timeline for the pivotal trial design alignment with the FDA.
- Supply Chain: Assess the risks associated with the single-source supplier in China for Auxora's active pharmaceutical ingredients and potential impacts from trade policies.
- Warrant Liability: Monitor the fair value fluctuations of the warrant liabilities, which significantly impact reported net income/loss but are non-cash items.